📊 CVSI Key Takeaways
Is CV Sciences, Inc. (CVSI) a Good Investment?
CV Sciences demonstrates severe operational distress with persistent negative profitability across all metrics and deteriorating cash flow generation. The company is consuming cash through operations while maintaining minimal liquidity reserves and substantial debt, creating an unsustainable financial position that threatens long-term viability.
CV Sciences shows weak fundamentals: revenue is shrinking, profitability remains negative, and returns on equity and assets are deeply unfavorable. While gross margin is still respectable and operating cash burn is modest, the balance sheet is fragile, with very limited cash, thin equity, weak quick liquidity, and negative interest coverage leaving little room for execution missteps.
CV Sciences, Inc. Key Strengths (CVSI)
- Reasonable gross margin of 48.5% indicates underlying product economics are viable at the production level
- Current ratio of 1.06x provides minimal short-term liquidity cushion
- Debt-to-equity ratio of 0.83x is moderate relative to total capitalization
- Gross margin of 48.5% indicates the core product economics are still viable
- Operating cash flow and free cash flow are only modestly negative, suggesting losses are not yet deeply cash-destructive
- Current ratio of 1.06x indicates the company is narrowly meeting near-term obligations on a headline basis
CVSI Stock Risks: CV Sciences, Inc. Investment Risks
- Negative operating cash flow of -53.0K combined with -153.0K free cash flow indicates the company is burning through capital reserves and cannot sustain operations from internal cash generation
- Negative net income of -752.0K with net margin of -7.2% and ROE of -48.9% demonstrate the company is not generating shareholder value and is destroying equity
- Quick ratio of 0.21x and cash position of only 381.0K relative to 5.5M in liabilities creates severe liquidity risk; company has less than 2 months of cash at current burn rate
- Revenue flat to declining (-1.9% YoY) while losing money indicates inability to achieve profitable scale or cost control
- No insider buying activity in last 90 days suggests management lacks confidence in near-term prospects
- Revenue declined year over year while net income remained negative, pointing to weak growth quality and limited operating leverage
- Liquidity is strained with only $381K of cash and a 0.21x quick ratio, increasing short-term financing risk
- Negative interest coverage, negative ROE of -48.9%, and only $1.54M of equity reflect a highly fragile financial position
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Operating cash flow trajectory and path to positive cash generation
- Revenue trend reversal and gross margin sustainability under cost pressure
- Debt refinancing obligations and covenant compliance
- Management changes or strategic pivots to achieve profitability
- Quarterly revenue growth and operating margin trend
- Cash balance and quick ratio
CV Sciences, Inc. (CVSI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
CV Sciences, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CVSI Profit Margin, ROE & Profitability Analysis
CVSI vs Healthcare Sector: How CV Sciences, Inc. Compares
How CV Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CV Sciences, Inc. Stock Overvalued? CVSI Valuation Analysis 2026
Based on fundamental analysis, CV Sciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CV Sciences, Inc. Balance Sheet: CVSI Debt, Cash & Liquidity
CVSI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CV Sciences, Inc.'s revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
CVSI Revenue Growth, EPS Growth & YoY Performance
CVSI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.2M | -$109.0K | $0.00 |
| Q3 2025 | $3.3M | -$109.0K | $0.00 |
| Q2 2025 | $3.6M | -$109.0K | $0.00 |
| Q1 2025 | $3.6M | -$109.0K | $0.00 |
| Q3 2024 | $3.9M | -$447.0K | $0.00 |
| Q2 2024 | $4.0M | -$584.0K | $0.00 |
| Q1 2024 | $4.0M | -$628.0K | $0.00 |
| Q3 2023 | $3.8M | -$447.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CV Sciences, Inc. Dividends, Buybacks & Capital Allocation
CVSI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CV Sciences, Inc. (CIK: 0001510964)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVSI
What is the AI rating for CVSI?
CV Sciences, Inc. (CVSI) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVSI's key strengths?
Claude: Reasonable gross margin of 48.5% indicates underlying product economics are viable at the production level. Current ratio of 1.06x provides minimal short-term liquidity cushion. ChatGPT: Gross margin of 48.5% indicates the core product economics are still viable. Operating cash flow and free cash flow are only modestly negative, suggesting losses are not yet deeply cash-destructive.
What are the risks of investing in CVSI?
Claude: Negative operating cash flow of -53.0K combined with -153.0K free cash flow indicates the company is burning through capital reserves and cannot sustain operations from internal cash generation. Negative net income of -752.0K with net margin of -7.2% and ROE of -48.9% demonstrate the company is not generating shareholder value and is destroying equity. ChatGPT: Revenue declined year over year while net income remained negative, pointing to weak growth quality and limited operating leverage. Liquidity is strained with only $381K of cash and a 0.21x quick ratio, increasing short-term financing risk.
What is CVSI's revenue and growth?
CV Sciences, Inc. reported revenue of $10.5M.
Does CVSI pay dividends?
CV Sciences, Inc. does not currently pay dividends.
Where can I find CVSI SEC filings?
Official SEC filings for CV Sciences, Inc. (CIK: 0001510964) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVSI's EPS?
CV Sciences, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CVSI's fundamental grade?
Based on our AI fundamental analysis in June 2026, CV Sciences, Inc. has a D grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CVSI stock overvalued or undervalued?
Valuation metrics for CVSI: ROE of -48.9% (sector avg: 15%), net margin of -7.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CVSI's AI grade for 2026?
Our dual AI analysis gives CV Sciences, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CVSI's free cash flow?
CV Sciences, Inc.'s operating cash flow is $-53.0K, with capital expenditures of $100.0K. FCF margin is -1.5%.
How does CVSI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7.2% (avg: 12%), ROE -48.9% (avg: 15%), current ratio 1.06 (avg: 2).